Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tepotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 19/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tepotinib SCHEMBL1296895 | 1.00 | MET (1.00) | METNQO2 | |
| Tepotinib SCHEMBL1296467 | 0.99 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL30259391 | 0.99 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL29550043 | 0.99 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL1295616 | 0.99 | MET (0.98) | METNQO2 | |
| SCHEMBL24713684 | 0.93 | MET (0.87) | METNQO2 | |
| SCHEMBL2462861 | 0.92 | MET (0.85) | METNQO2 | |
| SCHEMBL2530219 | 0.92 | MET (0.84) | METNQO2 | |
| SCHEMBL2514982 | 0.92 | MET (0.84) | METNQO2 | |
| Hydrochloric Acid SCHEMBL17823301 | 0.92 | MET (0.84) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531856-B1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK ABELLO AS (DK) | 2026-04-22 | — | — | EP | claimed |
| US-20250295655-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | Alk-Abelló A/S (DK) | 2025-09-25 | — | — | US | claimed |
| EP-4531856-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK-Abelló A/S (DK) | 2025-04-09 | — | — | EP | claimed |
| CN-118986988-A | Pharmaceutical preparation | 默克专利股份公司 | 2024-11-22 | — | — | CN | claimed |
| CN-118986987-A | Pharmaceutical preparation | 默克专利股份公司 | 2024-11-22 | — | — | CN | claimed |
| CN-114025761-B | Pharmaceutical preparation | 默克专利股份公司 | 2024-07-16 | — | — | CN | claimed |
| EP-4346829-A1 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | Merck Patent GmbH (DE) | 2024-04-10 | — | — | EP | claimed |
| WO-2023232958-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | Alk-Abelló A/S (DK) | 2023-12-07 | — | — | WO | claimed |
| WO-2022253935-A1 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | MERCK PATENT GMBH (DE) | 2022-12-08 | — | — | WO | claimed |
| EP-3996688-A1 | PHARMACEUTICAL PREPARATION | Merck Patent GmbH (DE) | 2022-05-18 | — | — | EP | claimed |
| WO-2022063869-A2 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | MERCK PATENT GMBH (DE) | 2022-03-31 | — | — | WO | claimed |
| CN-114025761-A | Pharmaceutical preparation | 默克专利股份公司 | 2022-02-08 | — | — | CN | claimed |
| US-20260137681-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN COMBINATION WITH HGF-RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | US | disclosed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4531856-B1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK ABELLO AS (DK) | 2026-04-22 | — | — | EP | disclosed |
| US-20250295655-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | Alk-Abelló A/S (DK) | 2025-09-25 | — | — | US | disclosed |
| EP-3996688-A1 | PHARMACEUTICAL PREPARATION | Merck Patent GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022063869-A2 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | MERCK PATENT GMBH (DE) | 2022-03-31 | — | — | WO | disclosed |
| CN-114025761-A | Pharmaceutical preparation | 默克专利股份公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-114025761-A | Pharmaceutical preparation | 默克专利股份公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137681-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN COMBINATION WITH HGF-RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | MET, HGF, EGFR | MET 1/4885NQO2 3935/4885 |
| US-20250295655-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | BTK, SYK, ABL1 | MET 4435/4885NQO2 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.